Review on early technology assessments of nanotechnologies in oncology

Abstract

Nanotechnology is expected to play an increasingly important role in the diagnostics, prognostics, and management of targeted cancer treatments. While papers have described promising results for nanotechnology in experimental settings, the translation of fundamental research into clinical applications has yet to be widely adopted. In future, policy makers will need to anticipate new developments for clinical implementation and introduce technology assessments. Here we present an overview of the literature on the technology assessments that have already been undertaken on early stage nanotechnology in cancer care, with particular emphasis placed on clinical efficacy, efficiency, logistics, patient-related features and technology dynamics.Owing to the current stage of development of most nanotechnologies, we found only a limited number of publications describing the application of either Health Technology Assessment (HTA) or Constructive Technology Assessment (CTA). In spite of the promising conclusions of most papers concerning the benefits of clinical implementation, actual clinically relevant applications were rarely encountered, and so far only a few publications report application of systematic forms of technology assessment. Most articles consider aspects of environmental safety, regulation and ethics, often mentioning the need to investigate such issues more thoroughly. Evaluation of financial and organizational aspects is often missing. In order to obtain a realistic perspective on the translation and implementation process there is a need for a broad and systematic evaluation of nanotechnologies at early stages of development. Assessment methods taking technology dynamics into account, such as Constructive Technology Assessment (CTA) should be considered for evaluation purposes. Published by Elsevier B.V. All rights reserved. IntroductionNanotechnology is a promising technology that is playing an increasingly important role in the diagnostics, prognostics,

EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization andin vitroevaluation

“…Polymer-based nanotechnology is a promising technology that is playing an increasingly important role in cancer treatment. Nanoscale devices can serve as targeted drug-delivery vehicles, carrying chemotherapeutic agents or therapeutic genes directly into cancer cells (Retèl et al, 2009). PEG-DSPE has been used to prepare liposomes or micelles capable of solubilizing hydrophobic drugs and delivering them to specific locations via targeting ligands conjugated to the particles.…”

Classifying US nano-scientists: Of cautious innovators, regulators, and technology optimists

“…Nanotechnology is embodied within a suite of the most promising technologies in the 21st century and is expected to be the technological foundation for future innovations (Pitkethly 2004;Retel et al 2009;Roco 2004;Siegrist et al 2007). Research and development investments in this field are growing rapidly throughout the world enabling wider applications of the technology (Roco et al 2011).…”

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation

“…Examples of this method can be found in studies on nanotechnology and gene array testing in breast cancer treatment [2, 3]. This can assist the researcher and product developers in identifying critical aspects that can influence or facilitate ultimate implementation and acceptance by professionals.…”